Muscarinic receptor agonists

Allergan and Sosei Halt Alzheimer’s Study

Alzheimer’s, Cognitive Issues, Dementia, Drug Safety, Drug Safety Concerns, FDA, Lewy Body Dementia (LBD), Muscarinic receptor agonists, Pharmaceuticals and Medical Device Agency (PMDA), R&D, Rare Tumors, Small Molecules

Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.

Allergan Buys Tobira for $1.695 Billion

Alzheimer's Disease, Business, Clinical Trials, DPP-IV Inhibitors, Fibrotic conditions, Health, Immunomodulator Drugs, Inflammation, M&A, Muscarinic receptor agonists, Neurodegenerative Diseases, Non-alcoholic steatohepatitis (NASH), R&D, Shares, U.S. Treasury Department

In yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.

Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares

Alzheimer's, Alzheimer's Diseases, Business, Cognitive Impairment, Health, M&A, M&A, Muscarinic receptor agonists, Psychosis

One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.